Patents by Inventor Melissa L. Fishel

Melissa L. Fishel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF APE1/REF-1 INHIBITORS FOR TREATMENT OF RETINAL DISEASES
    Publication number: 20230293471
    Abstract: Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
    Type: Application
    Filed: April 5, 2023
    Publication date: September 21, 2023
    Inventors: Mark R. Kelley, Melissa L. Fishel
  • Use of APE1/Ref-1 inhibitors for treatment of retinal diseases
    Patent number: 11648226
    Abstract: Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: May 16, 2023
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Mark R. Kelley, Melissa L. Fishel
  • USE OF APE1/REF-1 INHIBITORS FOR TREATMENT OF RETINAL DISEASES
    Publication number: 20210038553
    Abstract: Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
    Type: Application
    Filed: September 21, 2020
    Publication date: February 11, 2021
    Inventors: Mark R. Kelley, Melissa L. Fishel
  • SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
    Publication number: 20190382422
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: June 25, 2019
    Publication date: December 19, 2019
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • USE OF APE/REF-1 REDOX SPECIFIC INHIBITORS FOR TREATING METASTATIC PROSTATE CANCER
    Publication number: 20190365689
    Abstract: Methods of using redox APE1/Ref-1 inhibitors to treat prostate cancer, and particularly, metastatic prostate cancer, are disclosed. Particularly, small molecule inhibitors of APE1/Ref-1 redox activity have been found to decrease cell proliferation and induce cell cycle arrest in metastatic prostate cancer cell lines. Further, these APE1/Ref-1 redox inhibitors can be used to reduce expression of survivin, which has been shown to be overexpressed in primary and metastatic tumors.
    Type: Application
    Filed: January 25, 2018
    Publication date: December 5, 2019
    Inventors: Mark R. Kelley, III, Travis Jerde, Melissa L. Fishel
  • Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
    Patent number: 10377780
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: August 13, 2019
    Assignees: The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • USE OF APE1/REF-1 INHIBITORS IN COMBINATION THERAPIES FOR TREATMENT OF CANCER
    Publication number: 20190160034
    Abstract: Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
    Type: Application
    Filed: March 20, 2018
    Publication date: May 30, 2019
    Inventors: Mark R. Kelley, Melissa L. Fishel
  • SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
    Publication number: 20170267704
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: March 30, 2017
    Publication date: September 21, 2017
    Applicants: The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
    Patent number: 9650399
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: May 16, 2017
    Assignees: The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • Compounds and methods for treating leukemia
    Patent number: 9315481
    Abstract: Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (ALL) in its various forms.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 19, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Mark R. Kelley, Melissa L. Fishel, Angelo A. Cardoso
  • SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
    Publication number: 20150158894
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Application
    Filed: May 24, 2013
    Publication date: June 11, 2015
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • COMPOUNDS AND METHODS FOR TREATING LEUKEMIA
    Publication number: 20150018355
    Abstract: Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (ALL) in its various forms.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 15, 2015
    Inventors: Mark R. Kelley, Melissa L. Fishel, Angelo A. Cardoso